NovoCure Limited

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2026-02-13 pm EST			5-day change	1st Jan Change
10.99 ^USD	-12.29%		+8.38%	-15.00%

Feb. 12	FDA approves first-of-its-kind device to treat pancreatic cancer	RE
Feb. 12	Sector Update: Health Care Stocks Rise Late Afternoon	MT

Published on 02/22/2024 at 08:00 am EST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good day, and thank you for standing by. Welcome to the NovoCure Q4 2023 Earnings Conference Call. [Operator Instructions] Please be advised that

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Feb. 12	FDA approves first-of-its-kind device to treat pancreatic cancer	RE
Feb. 12	Sector Update: Health Care Stocks Rise Late Afternoon	MT
Feb. 12	Sector Update: Health Care Stocks Higher Thursday Afternoon	MT
Feb. 12	Sector Update: Health Care	MT
Feb. 12	Sector Update: Health Care Stocks Fall Pre-Bell Thursday	MT
Feb. 12	Top Premarket Gainers	MT
Feb. 12	North American Morning Briefing : Stock Futures Rise Ahead of More Earnings, Inflation Data	DJ
Feb. 12	Novocure Says FDA Approves Locally Advanced Pancreatic Cancer Treatment; Shares Up Pre-Bell	MT
Feb. 12	PRESS DIGEST-Wall Street Journal - February 12	RE
Feb. 11	U.S. FDA Approves Novocure's Optune Pax®? for the Treatment of Locally Advanced Pancreatic Cancer	CI
Jan. 14	NovoCure Limited Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 09:45 AM
Jan. 12	NovoCure Reports Rise in Q4 Preliminary Revenue	MT
Dec. 01	Novocure Limited Announces CEO Changes	CI
Dec. 01	Novocure appoints company president Frank Leonard as chief executive officer	RE
Dec. 01	NovoCure Names Frank Leonard as Chief Executive	MT